Kyverna Therapeutics Announces JAMA Neurology Publication of Registrational Miv-cel Data in Stiff Person Syndrome
EMERYVILLE, Calif., Nov. 9, 2026 – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company developing transformative therapies for neurological autoimmun...
